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The increase in lung cancer incidence of Korea has been dampened since 2000; 
however, increased human lifespan, interest in health care and the widespread 
implementation of health examinations have resulted in a considerable rise in 
detection of small lesions that need to be differentiated from lung cancer. De-
tection of lung cancer at an early stage rather than at a symptomatic advanced 
stage is also increasing, suggesting that there are increasing diagnostic de-
mands for small peripheral lung lesions. The development of new molecular 
diagnostics, including next generation sequencing, companion diagnostics that 
accompany development of new anti-cancer drugs, and re-biopsy for application 
of new therapeutic modality accelerate the development of lung cancer diag-
nostics. In this review, we extensively describe the current available diagnostic 
tools in lung cancer.
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INTRODUCTION 
According to the annual report of the Korean National 
Cancer Registration Statistics, the crude incidence of 
lung cancer per 100,000 people in 2016 was 50.4, the 4th 
highest among all cancers, following that of stomach, co-
lon, and thyroid cancer. Lung cancer incidence appears 
to have continuously increased from 1997, with 52.7 crude 
incidence rate per 100,000 people in the year 2017; how-
ever, based on the age-adjusted ratio, it has remained 
steady since 2005, peaking at 28.9 cases per 100,000 peo-
ple (Fig. 1) [1]. This tendency is slightly different in male 
versus female population, with lung cancer incidence 
gradually decreasing for the former but still slowly in-
creasing for the latter; this may be attributed to a decline 
in male smokers versus a rise in female smokers [2]. 
According to the 2018 report on the cases of death from 
the Statistics Korea, 26.5% of all deaths were cancer-relat-
ed. Among all cancer-related deaths, the crude mortality 
rate due to lung cancer reached 34.8 cases per 100,000 
people, and it was more than that from other cancer 
types (Fig. 2) [3,4]. Despite this, the 5-year relative surviv-
al rate for lung cancer has improved dramatically from 
11.3% in the first survey period (1993 to 1995) to 28.2% 
(2012 to 2016). However, its survival-related prognosis is 
still the second worst following that of pancreatic cancer, 
with an 11.4% 5-year survival rate (survey period: 2012 to 
2016). These findings imply that majority of lung cancer 
patients are diagnosed at advanced stages which cannot 
be cured by surgery or other therapeutic modalities, but 
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also indicate that there are great demands for improve-
ment in the diagnosis and treatment. Recently, to stan-
dardize the diagnosis and treatment of lung cancer, the 
Korean Health Insurance Review and Assessment (HIRA) 
has developed indicators, applied evaluation guidelines 
and reported the results [5]. Moreover, in July 2019, Ko-
rean national lung cancer screening projects using low-
dose chest computed tomography (CT) were launched 
for groups at high-risk for lung cancer. In this review, we 
discuss the diagnostic methods currently widely used for 
the diagnosis of lung cancer and describe their advantag-
es and limitations. 
CLINICAL MANIFESTATIONS
Symptoms of lung cancer can be classified into two cat-
egories: caused by the direct mass effect or invasion of 
the tumor or by paraneoplastic symptoms, which are 
systemic symptoms that are due to substances secreted 
by the tumor (Table 1). Symptoms owing to direct tumor 
invasion include cough, hemoptysis, wheezing, shortness 
of breath, obstructive pneumonia due to endobronchial 
growth of the primary tumor, and chest wall pain and 
shortness of breath due to restrictive dysfunction owing 
to peripheral growth of the tumor. Regional spread of 
tumor into the thorax can also cause symptoms depend-
ing on the involved organs. Invasion of the trachea by 
the tumor may result in dyspnea, invasion of the esoph-
agus can cause dysphagia, involvement of the recurrent 
laryngeal nerve causes hoarseness, and diaphragmatic 
nerve involvement leads to respiratory distress related to 
diaphragm paralysis. In addition, invasion of the sympa-
thetic nerves of the cervical spinal cord causes Horner’s 
syndrome, characterized by enophthalmos, ptosis, mi-
osis, and anhydrosis. Pancoast syndrome, caused by the 
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invasion of the 8th cervical and 1st or 2nd thoracic nerve, 
presents as shoulder pain radiating along with the ulnar 
nerve distribution, and invasion of the superior vena 
cava leads to superior vena cava syndrome [6,7]. Lung 
cancer can metastasize to any organ in the body, which 
leads symptoms related to the metastatic lesion.
Paraneoplastic syndromes can occur in case of both 
benign and malignant tumors but are not correlated to 
the tumor mass or invasion, and are more commonly 
observed in tumors with a neuroendocrine origin. They 
occur in approximately 10% of lung cancer patients. 
Humoral hypercalcemia of malignancy, syndrome of 
inappropriate antidiuretic hormone secretion (SIADH), 
and ectopic Cushing’s syndrome represent the most 
commonly reported symptoms. It is often challenging 
to distinguish symptoms caused by metastases of the 
carcinoma, and inappropriate diagnosis is associated 
with inappropriate treatment. Therefore, special atten-
tion is required when these particular symptoms are 
noted. Hypercalcemia is a life threatening complication 
often observed in lung squamous cell carcinoma and 
is caused by the ectopic secretion of the parathyroid 
hormone (PTH) or the PTH-related peptide inducing 
symptoms such as frequent urination, thirst, vom-
iting, nausea, abdominal pain, constipation, and, in 
severe cases, loss of consciousness. Hyponatremia in 
SIADH caused by the ectopic secretion of atrial natri-
uretic peptide can also occur frequently and requires 
careful evaluation as it may lead to loss of conscious-
ness or death due to cerebral edema. Small cell lung 
cancer and bronchial carcinoid tumors may also lead 
to the development of Cushing’s syndrome caused by 
an ectopic secretion of the adrenocorticotropic hor-
mone and other hormones that can lead to neurologic 
symptoms owing to the formation of auto-antibodies 
[8]. In any case, if symptoms occur, it is likely that the 
disease is impossible to cure; thus, careful monitoring 
and accurate diagnoses must be carried out to improve 
prognosis in these patients. If suspected lung cancer 
lesions are found in high-risk patients or in previous 
examinations, it is necessary to accurately identify the 
nature of the lesion and conduct appropriate tests in 
a timely fashion, preferably prior to the occurrence of 
other symptoms.
Table 1. Symptoms from lung cancer
Comments
Symptoms from direct tumor invasion
Symptoms associated with central or endobronchial 
  growth of tumor
Cough, hemoptysis, wheezing, shortness of breath, 
  obstructive pneumonia
Symptoms associated with peripheral growth of tumor Pleural and chest wall pain, dyspnea
Horner’s syndrome Sympathetic nerve paralysis; enopthalmos, ptosis,  miosis 
  and anhydrosis
Pancoast syndrome Involvement of the 8th cervical and 1-2nd thoracic nerve, 
  shoulder pain radiating ulnar distribution of the arm.
Superior vena cava syndrome Facial edema, right arm edema
Symptoms associated with extra-thoracic metastatic disease
Paraneoplastic syndromes
Humoral hypercalcemia of malignancy Ectopic secretion of PTHrP, Squamous cell lung cancer
Syndrome of inappropriate antidiuretic hormone secretion Ectopic secretion of vasopression, common in the tumor with 
  neuroendocrine features, such as small cell lung cancer
Ectopic Cushing's syndrome Ectopic ACTH production, common in neuroendocrine 
  tumor, such as small cell lung cancer
Skeletal-connective tissue syndrome Clubbing, hypertrophic primary osteoarthropathy, 
Neurologic-myopathic syndoromes Eator-Lambert syndrome, retinal blindness with SCLC, 
  peripheral neuropathies, subacute cerebellar degenration, 
  corical degernation, polymyositis
 PTHrP, parathyroid hormone-related peptide; ACTH, adrenocorticotropic hormone.
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IMAGING STUDIES
Several imaging modalities can be used for the diag-
nosis and staging of patients with lung cancer. In re-
al-world practice, combination of several imaging stud-
ies is needed to ensure accuracy of the diagnosis.
Chest CT
Chest CT is a fundamental imaging tool for the eval-
uation of lung cancer and is most commonly used as 
a noninvasive modality for the screening and staging 
of lung cancer. It is especially useful to define the size, 
location, and characterization of lung lesions, which are 
surrounded by air-filled lung tissue. Additionally, me-
diastinal and hilar lymphadenopathy, pleural effusion, 
metastasis in the liver, adrenal glands, bone, and other 
parts of the thoracic cavity can be assessed by chest CT. 
Since September 2019, low-dose chest CT (LDCT) has 
been adopted? for the screening of lung cancer in high-
risk individuals in Korea. Screening with LDCT rather 
than conventional chest radiography is efficient to de-
tect small lung nodules, leads to early intervention, and 
improves prognosis of lung cancer patients. The U.S. 
National Lung Cancer Screening Trial demonstrated 
that LDCT screening leads to a 20% reduction in lung 
cancer-associated mortality in high-risk populations 
compared to that seen with chest X-ray. Patients with 
positive results after LDCT need to be further evaluated 
using other diagnostic procedures [9].
Positron emission tomography-CT
Positron emission tomography (PET), using uptake of 
the radiolabeled glucose analogue [18F]-fluoro-2-dox-
yglucose by metabolically active cells, is a useful test 
for staging and thus deciding a treatment modality. It 
is also useful for the detection of extrathoracic disease. 
However, a false negative result may occur in cases 
of small lesions less than 1 cm in size and in tumors 
with low metabolic activity such as in case of carcinoid 
tumors or bronchioloalveolar cell carcinoma. In con-
trast, false positives can also occur when inflammatory 
conditions, such as pneumonia or granulomatous 
disease, are present. According to a report by Lee et al. 
[10], the false positive rates for PET-CT in the identifi-
cation of mediastinal lymph node (L/N) metastasis in 
Korea can be as high as 87% when using endobronchial 
ultrasound-guided transbronchial needle aspiration 
(EBUS-TBNA) as a gold standard and significantly 
higher in patients older than 65 years with squamous 
cell carcinoma or pneumoconiosis. However, the same 
study reported that current or past history of tubercu-
losis did not significantly affect the false positive rate, 
unlike previous reports indicating that the usefulness 
of PET-CT decreased in areas with a high prevalence of 
tuberculosis [10]. 
Brain magnetic resonance imaging 
Lung cancer, along with breast and malignant melano-
ma, are common causes of brain metastases, with lung 
cancer being the most common. Brain metastases can be 
detected as an early symptom in approximately 10% of 
diagnosed patients and associated with significant mor-
bidity and limited survival [11]. The presence of symp-
tomatic brain metastases is an important consideration 
in the selection of therapeutic agents and treatment 
modality. As the survival of lung cancer patients increas-
es, improvement of drug permeability of the blood-
brain barrier has become an important consideration for 
pharmaceutical companies when developing anti-cancer 
drugs. HIRA guidelines recommend assessment of brain 
metastases for initial staging and preoperative evaluation 
of lung cancer [5]. However, with the recent increase in 
the early diagnosis of lung cancer, the need for brain 
magnetic resonance imaging (MRI) for staging tumors 
less than 2 cm in size has been questioned [12].
Whole body bone scintigraphy 
Approximately 30% to 40% of non-small cell lung cancer 
(NSCLC) patients develop bone metastases that lead to 
poorer prognosis and worsen quality of life during the 
remaining life. Whole body bone scintigraphy (WBBS) 
is useful for the detection of bone metastases, when 
used in conjunction with other relevant clinical findings 
such as bone pain, elevated alkaline phosphatase, and 
hypercalcemia. It also has a high false positive rate due 
to trauma, inflammation and degenerative change of 
skeletal system and thus, the routine use of WBBS is not 
recommended by the National Comprehensive Cancer 
Network guidelines [13]. Moreover, implementation of 
WBBS for lung cancer is on the decline in Korea as the 
HIRA indicator does not include bone scans as imaging 
tools conducted for lung cancer bone metastasis [5].
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BIOPSY PROCEDURES
Nowadays, biopsy has become indispensable not only 
for the diagnosis of lung cancer by confirming the 
presence of lung cancer cells but also for selection of 
appropriate treatment by molecular genetic testing. 
There are several tools for lung tissue biopsy that are 
currently used for diagnosis and staging of lung can-
cer. Selection of the diagnostic tools should take into 
account invasiveness and accuracy but also the location 
and characteristics of the lesion, the general condition 
of the patient, and the level of experience of the techni-
cian performing the examination (Table 2). 
Fiberoptic bronchoscopy 
The bronchial pathway to the target lesion and location 
where the sampling to be performed using forceps and 
brushes should be determined by careful review of the 
patient’s anatomy before fiberoptic bronchoscopy (FBS) 
procedure. The diameter of commercial FBS is around 
6 mm and lesions locating up to subsegmental bron-
chus can be detected and biopsied using FBS. The di-
agnostic yield for FBS is low, ranging from 20% to 60% 
[14]. The size and location, and visibility of lesion are 
important factors that influence the diagnostic yield. 
Lung lesions less than 2 cm in diameter located in pe-
ripheral lung areas typically lead to low yields. In the 
case of endobronchial lesions that are located in central 
regions, three or more biopsies are recommended to 
achieve high diagnostic yields. Transbronchial biopsy, 
bronchial washing, and bronchial brushing can also 
improve the diagnostic yield for the lesions that are not 
directly visible by FBS. For peripheral lung lesions that 
cannot be reached by routine FBS, fluoroscopy guided 
transbronchial lung biopsy can increase the accuracy 
of the diagnosis. Recently, other fusion techniques, in-
cluding EBUS and navigation bronchoscopy, have been 
developed and used to improve diagnostic yield.
EBUS-TBNA
EBUS-TBNA, which was introduced to identify medias-
tinal L/N metastasis of lung cancer, is now widely used 
Table 2. Advantages and disadvantages of commonly used biopsy procedures for lung cancer
Advantages Disadvantages
FBS High diagnostic yield for central and endobronchial  
  lesion
Low diagnostic yield for non-endobronchial lesion 
  and peripheral lesion
EBUS-TBNA Acquisition of real-time ultrasound images
Accessibility to central lung lesion and some L/N 
  (located in mediastinal, paratracheal, subcarinal, 
  hilar, and interlobar area)
Collection of cell and some lung tissue
Limitation in evaluationg peripheral lung lesion and 
  other L/N
EBUS-GS Acquisition of real-time ultrasound images
Improved accessibility to more peripheral lesion
Collection of cell and some lung tissue
Requirement of professional training
Expensivenss
Navigation 
  bronchoscopy
Acquisition of reconstructed and a virtual road map 
  to target
Improved accessibility to more peripheral lesion
Collection of cell and some lung tissue
Requirement of navigation program
Expensiveness
CT-NAB High diagnostic yield for peripheral lung lesion 
  (diameter > 2 cm)
Collection of cell and some lung tissue
Need of patient's cooperation (Keep posture and 
  holding breath)
Gun biopsy High diagnostic yield using core-biopsy needles
Collection of relatively sufficient lung tissue
Need of patient's cooperation (Keep posture and 
  holding breath)
Relatively prevalent complication: pneumothorax 
  and pulmonary hemorrhage
FBS, fiberoptic bronchoscopy; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; L/N, lymph 
node; EBUS-GS, endobronchial ultrasound using a guide; CT-NAB, needle aspiration biopsy with CT guidance.
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not only for the examination of L/N but also for the 
identification and biopsy of central lesions that cannot 
be reached by FBS. The EBUS-TBNA needle is typically 
inserted through the wall of the trachea or main bron-
chus into the mass or the lymph node. During this pro-
cedure, the position of the target lesion is confirmed 
based on real-time ultrasound images [15]. The highest 
mediastinal, upper paratracheal, lower paratracheal, 
subcarinal, hilar, and interlobar L/Ns can be assessed 
using this methodology with low complication rate [16]. 
However, the para-aortic, aortopulmonary window or 
subaortic, paraesophageal, and pulmonary ligament 
L/Ns are not accessible through this technique. The 
diagnostic yield for EBUS-TBNA is high with a sen-
sitivity of 90% and a negative predictive value of 93% 
[17]. In patients with negative results in a standard FBS, 
EBUS-TBNA was able to confirm primary central lung 
cancer with a sensitivity of 77% [18].
EBUS using a guide sheath 
Using a radial EBUS probe, it is possible to detect pe-
ripheral lung lesions surrounding the tip of the probe. 
The image of radial-type EBUS can be obtained using a 
guide sheath (GS). Biopsy forceps and bronchial brush-
es can be placed using GS. This method is superior to 
FBS or EBUS accessing small peripheral lung lesions 
[14]. The accessible airways closest to the lesion are 
marked as targets. The radial probe is then inserted 
into the target lesion through the bronchoscope. After 
retraction of the radial probe, forceps or brushes can be 
placed to further biopsy target lesions. Until recently, 
the diagnostic yield and safety of EBUS-GS have not 
been fully evaluated. Most studies investigating this 
issue were based on single center case reports or were 
meta-analyses. However, a larger number of studies 
have now shown the good diagnostic yield of EBUS-
GS and confirmed that it is a well-tolerated procedure 
[14,19,20].
Navigation bronchoscopy
Navigation bronchoscopy is generally adopted for small 
peripheral lung lesions to increase diagnostic accuracy. 
This technique includes three stages. In the first stage, 
or the planning stage, a CT scan is reconstructed and a 
virtual road map to the target is created. In the second 
stage, or registration stage, an electromagnetic field is 
created around the body using sensors to overlap the 
virtual and the actual body. The last stage is the navi-
gation stage where the above information is used for 
navigation to guide the probe to the target site [21]. The 
diagnostic yield of this method has been found to range 
from 33% to 97% [22]. Incidence of pneumothorax is the 
most frequent complication for this method and occurs 
in approximately 3% of all cases [23]. The technician’s 
expertise; the volume, location, and characteristics of 
the lung lesions; concurrent EBUS; and the use of cath-
eter aspiration are important factors that can influence 
the diagnostic yield of this method.
Transthoracic needle aspiration biopsy with CT 
guidance 
CT-needle aspiration biopsy (NAB) is one of the most 
commonly used tools to secure lung tissue, and its 
diagnostic yield is dependent on the size of the target 
lung lesion. Typically, lung nodules over 1 to 2 cm in 
size are good candidates for CT-NAB. Previous stud-
ies have shown that the diagnostic yield for CT-NAB 
ranged from 77% to 94%. It is an invasive procedure 
and can provide an alternative to surgery for the con-
firmation of lung cancer diagnosis. However, this 
technique is associated with a risk of complications. A 
recent study revealed that the associated rates of pneu-
mothorax and bleeding were 20% and 3%, respec-
tively [24]. Another study showed that pneumothorax 
requiring intervention occurred in 4.3% of patients, 
and that major complications developed in 4.4% of 
those patients [25]. Larger needle diameters, increased 
transverse lung parenchyma, and smaller lesion sizes 
are risk factors for the development of major compli-
cations in this procedure [25]. Contraindications to 
the use of CT-NAB are bleeding diathesis, low platelet 
count, prolonged prothrombin time or partial throm-
boplastin time and international normalized ratio, 
pulmonary hypertension, emphysematous disease and 
chronic obstructive pulmonary disease, large bullae 
in the biopsy path, and patients with challenges such 
as intractable cough or those using mechanical ven-
tilation. The ability of patients to hold their breath 
and maintain their position is important for this 
procedure. A careful selection of patients is needed in 
order to attain better yields and reduce complication 
rates. Recently, improvements have been made to this 
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technique including the addition of laser guidance to 
improve its accuracy and reduce the risk of complica-
tions [26].
Gun biopsy
Various types of needles are available for CT-NAB and 
the choice of needle is dependent on the size, location, 
and characteristics of the target lesions, and the tech-
nician’s expertise and preference. There are mainly 
three types of needles used: aspiration needles, cutting 
needles, and automated core biopsy needles. Aspiration 
needles are thin-walled and flexible, and cellular mate-
rial for microscopic or cytological diagnosis can be ob-
tained using these needles [27]. Cutting needles, which 
are modified aspiration needles with a side cutting tip, 
are used to obtain histologic specimens. Lastly, core 
biopsies can be performed using a biopsy gun without 
causing crushing injuries. Specimens obtained from 
core biopsies increase the rate of definite benign dis-
ease and allow for the characterization of different cell 
types. The diagnostic yield of core biopsy is superior 
to that of CT-NAB particularly in benign disease and 
specimen obtained from core biopsy is more suitable 
for immunochemical and genetic variation test com-
pared to that from fine needle aspiration. On the other 
hand, it has an increased associated risk of complica-
tions. The reported overall complication rate and ma-
jor complication rate are 38% and 6%, respectively, for 
this technique. In a previous study, pneumothorax and 
pulmonary hemorrhage developed in 25% and 18% of 
patients, respectively [25]. The choice of biopsy needle 
for transthoracic needle biopsies should be considered 
on a case-by-case basis for the improvement of the di-
agnostic yield, purpose of biopsy, and the reduction in 
the rate of complications. 
LABORATORY TESTS
Genomic alterations are an important cause of cancer 
initiation, growth, and progression. Various techno-
logical advancements in cancer genomic analysis plat-
forms have made possible the identification of genomic 
alterations that can impact the therapeutic response in 
lung cancer. Therefore, genetics/genomics research is 
actively being conducted in the lung cancer field, and 
factors such as EGFR, ALK, and ROS1 have been iden-
tified and are currently being used as targets for lung 
cancer treatment. In addition, data regarding mutations 
in genes such as BRAF, VEGF, KRAS, RET, and MET are 
also being used for cancer treatment, in addition to im-
munological markers such as programmed cell death 
(PD)-1 and PD ligand 1 (PD-L1) (Table 3) [28].
Polymerase chain reaction based tests
Polymerase chain reaction (PCR) is a revolutionary 
Table 3. Commonly used molecular markers for lung cancer in Korea
Molecular marker Prevalence (in Korea) Most common mutation Molecular method Available medicine
EGFR mutation 20%–56% in 
  adenocarcinoma
E19del, L858R RT-PCR, Sanger 
  sequencing, NGS
Osimertinib, gefitinib, 
  afatinib, dacomitinib 
  erotinib
ALK 3%–5% in NSCLC EML4-ALK fusion FDA-approved IHC, 
  FISH, NGS
Alectinib, crizotinib, 
  ceritinib, brigatinib
ROS1 2%–3% in 
  adenocarcinoma
CD74, SLC34A2, 
  CCDC6, FIG
FDA-approved IHC, 
  FISH, NGS
Crizotinib
BRAF 1.8% in adenocarcinoma V600E RT-PCR, Sanger 
  sequencing, NGS
Dabrafenib, trametinib
PD-1/PD-L1 
  expression (≥ 1%)
42% FDA-approved IHC Nivolumab, 
  pembrolizumab, 
  atezolizumab, 
  durvalumab
RT-PCR, reverse transcription polymerase chain reaction; NGS, next generation sequencing; NSCLC, non-small cell lung can-
cer; FDA, food and drug administration; IHC, immunohistochemistry; FISH, fluorescent in situ hybridization.
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method invented in 1983 that allows for large amounts 
of DNA to be amplified in vitro using two primers. PCR-
based assays have been continually amended to make 
it easier to find driver mutations such as EGFR in the 
medical practice. Dideoxynucleotide sequencing, de-
veloped by Sanger et al. [29], of PCR-amplified DNA 
is the standard method for the detection of genomic 
mutations; however, it shows suboptimal sensitivi-
ty, is labor- intensive, and has long turnover times. 
Other modified methods, such as PCR-single-strand 
conformation polymorphism, TaqMan PCR, Cycleave 
PCR, PCR-restriction length polymorphism, peptide 
nucleic acid-locked nucleic acid PCR clamp, and mu-
tant-enriched PCR, have been developed and showed 
improved sensitivity when compared to conventional 
PCR methods. Kim et al. [30] compared the PNA-medi-
ated PCR clamping method and the direct-sequencing 
method using the tissues of 112 lung cancer patients. 
They demonstrated that mutants were identified in 45 
samples using the PNA-mediated clamping method, 
10-fold more than that when using direct-sequencing, 
and indicated that this method can be useful for detect-
ing driver mutations [31]. Now, PNA-mediated clamping 
method is one of the most commonly used methods to 
detect driver mutations in cancer tissue specimen in 
Korea.
Next generation sequencing based tests
Next generation sequencing (NGS) is a methodology 
that quickly decodes a large amount of genome infor-
mation by breaking down a genome into numerous 
fragments, reading each fragment simultaneously, and 
finally combining the data obtained using bioinformat-
ics techniques [32]. Hybrid capture sequencing is used 
when whole genome, whole exome, or large targeted 
panels are assessed, whereas amplicon sequencing is 
used when in-depth reading is required and assay sen-
sitivity is being evaluated. Targeted NGS panels have 
been validated in several previous studies. Targeted 
NGS panels, including those for EGFR, KRAS, BRAF, 
and MET, are widely used in lung cancer [33]. Wider 
analyses can take up to a week to complete. From these 
large NGS datasets, in addition to EGFR, KRAS, and 
BRAF mutations, 36% of lung cancer patients can be 
found to harbor other potential driver mutations (FGFR, 
ERBB2, AKT, and MAP2K1, STK11) [34-36]. Many NGS 
panels that include more diverse genes, tumor muta-
tional burden, microsatellite instability status detec-
tion, and fusions are currently under development and 
will provide more detailed information on lung cancer 
genetics. Since 2017, the NGS technology base genetic 
panel test has been designated as an object for national 
health insurance benefits in Korean lung cancer pa-
tients. When applying NGS in lung cancer in Korea and 
claiming insurance, the essential requirements of the 
genetic panel should include following 14 genes; HER2, 
EGFR, ALK, KRAS, NRAS, BRAF, BRCA1, BRCA2, KIT, 
PDGFRA, IDH1, IDH2, MYC, MYCN [37]. However, NGS 
can yield false negatives or positives, and therefore, ad-
ditional tests such as fluorescence in situ hybridization 
or immunohistochemistry (IHC) for protein overex-
pression may improve the patients’ diagnosis.
Real-time PCR
There are two types of commonly used real-time PCR 
methods: real-time PCR using a TaqMan probe and 
real-time PCR using SYBR Green. Although tissue bi-
opsies are the gold standard for detecting driver muta-
tions, they are invasive and sometimes challenging to 
obtain due to the patient’s condition and tumor loca-
tion or size. Contrary to tissue biopsy, a liquid biopsy 
from plasma, pleural effusion, or bronchoalveolar la-
vage fluid is typically less invasive [38]. Previous studies 
have shown promising data using liquid biopsies and 
real-time PCR [39]. Shin et al. [39] reported a 100% sensi-
tivity and concordance rate of 98.7% with real-time PCR 
for EGFR using pleural effusions when compared to 
Sanger sequencing and PNA-mediated PCR clamping.
Transcriptome analysis
In transcriptome analysis, analysis is performed using 
microarray, an RNA sequencing method that separates 
mRNA, converts it into cDNA, and analyses its sequence 
using NGS. Whole transcriptome profiles can easily be 
obtained from Gene Expression Omnibus (GEO) data-
bases. Lim et al. [40] integrated robust datasets into the 
bioinformatics pipeline using statistical methods and 
presented normalized datasets in lung cancer. Bang et 
al. [41] conducted transcriptome analyses for 10 NSCLC 
patients and reported that genes related to the cell cycle 
were highly upregulated in lung cancer. They validated 
these results using public data available in GEO and 
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The Cancer Genome Atlas (TCGA). MFAP4 and AGER 
genes were significantly downregulated and the SPP1 
gene was upregulated in NSCLC, and these genes were 
significantly associated with poorer prognoses. 
Transcriptome alterations associated with lung can-
cer can easily be identified using tissue samples for ear-
ly detection, screening, and prevention of lung cancer 
[42]. Several studies have reported the effects of smok-
ing on the transcriptome of thoracic airway epithelium 
and showed that genes related to oxidative stress, apop-
tosis, profibrosis, mucin production, anti-oxidants, 
anti-proteases, and immune-related processes were 
enriched. Silvestri et al. [43] prospectively evaluated a 
bronchial-airway gene-expression classifier to improve 
the diagnostic performance of FBS in 639 patients with 
suspected lung cancer and found that it improved the 
sensitivity of lung cancer diagnosis.
IHC tests
IHC is used in the differential diagnosis of adenocarci-
noma and squamous carcinoma (SqCC); neuroendocrine 
marker identification; driver mutation assessment, 
including that for EGFR/ALK/ROS1 and PD-L1/PD-1 ex-
pression; and the differential diagnosis of lung cancer 
and mesothelioma [7]. Thyroid transcription factor-1 
and napsin A are used as adenocarcinoma markers, and 
p40, CK5/6, and TP63 can be used as SqCC markers [44]. 
According to World Health Organization classification, 
assessment of both neuroendocrine morphology and 
immunohistochemical expression (chromogranin A, 
synaptophysin, or CD56) is required for the diagnosis of 
large cell neuroendocrine carcinoma. For the detection 
of driver mutations, the U.S. Food and Drug Admin-
stration (FDA)-approved ALK D5F antibody is used for 
ALK-rearranged NSCLC as a companion diagnostic tool 
[45]. However, IHC analysis is not used in EGFR muta-
tion screening due to its low sensitivity. IHC methods 
for PD-L1/PD-1 varies between providers. The U.S. FDA 
approved the 22C3 antibody for pembrolizumab, the 
28-8 antibody for nivolumab, and SP142 for atezolizumab 
[46]. Many studies have reported that PD-L1/PD-1 levels 
correlate to treatment response and prognosis; however, 
further research will be needed to fully understand these 
pathways in cancer [47]. Calretinin, BAP1, podoplanin, 
CK5, CK5/6, and WT1 can be potentially used for the di-
agnosis of mesothelioma [48].
FUTURE DIAGNOSIS FOR LUNG CANCER
With the continuous development of new therapeutic 
modalities for lung cancer, the demand for re-biopsy 
has grown concurrently along with the increase in sur-
vival rates. Companion diagnostics, including immu-
nochemical, genetic, and transcriptome analyses, for 
application of lung cancer therapeutic agent are associ-
ated with an increasing demand for a large amount of 
fresh tissue. However, it is often not feasible to perform 
additional invasive tests to obtain fresh specimens, 
especially in patients who have experienced relapses 
during long-term anti-cancer treatment. Therefore, 
in addition to the development of safe and convenient 
techniques for obtaining fresh tissues, sensitive lab-
oratory diagnostic methods that can obtain accurate 
results with a small amount of specimen should be 
developed. In this regard, liquid biopsy using blood has 
drawn much attention, but is only useful in patients 
with an advanced disease stage and has limitations in 
those with small tumor burden [49]. The utility of cir-
culating tumor cells (CTCs) and circulating tumor DNA 
(ctDNA) in liquid biopsies has been extensively evalu-
ated. Research on CTCs is waning little by little due to 
the lack of biomarkers that can accurately identify and 
secure CTCs except epithelial cell adhesion molecule 
(EpCAM) and to additional requirement for high effi-
ciency platforms that enrich and enumerate CTCs [50]. 
On the other hand, the clinical usefulness of ctDNA is 
gradually increasing due to the development of ctDNA 
preservation and detection technology. 
Also, there have been advances not only in bron-
choscopy techniques itself but also in adjuvant therapy 
administered before and after the procedures. EBUS is 
now standardized diagnostic tool for lung cancer diag-
nosis and mediastinal L/N staging and EBUS-GS have 
been introduced at a number of medical institutions 
in Korea. EBUS-GS has the advantage of being able to 
reach peripheral small lung lesions and is useful for 
obtaining tissues. Diagnostic yield of EBUS-GS brush-
ing cytology alone is not still satisfactory, requiring 
development of technologies that can increase the 
diagnostic yield [9]. In contrast, the introduction of 
navigation bronchoscopy is relatively slow, possibly 
because it serves the similar purpose as EBUS-GS in 
examining small peripheral lesions but is cost-inten-
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sive and requires additional facilities. The lungs are 
mostly composed of air-filled loose tissue that makes 
exact examination of the entire lung structure difficult 
using MRI or ultrasonography alone. However, novel 
diagnostic tools are being developed by overcoming 
the shortcomings of different methods and combining 
their advantages. One example is EBUS, a combination 
of ultrasound and optical bronchoscopy, employing 
navigation of the bronchoscope based on CT image 
analysis.
CONCLUSIONS
Increasing interest in health, regular check-ups, and 
development of new treatment modalities has led to 
increasing demands for procurement of tissue for rou-
tine diagnosis but also companion diagnostics. In this 
review, we discussed the diagnostic methods for lung 
cancer that are widely used in current medical prac-
tice, and we described their advantages and limitations 
including complementary relation between different 
diagnostic tools with the aim of contributing to the ap-
propriate selection and application of these techniques 
in lung cancer patients.
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